Literature DB >> 21669870

Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4+ T cells and B cells.

Pascaline Charlot-Rabiega1, Emilie Bardel, Céline Dietrich, Robert Kastelein, Odile Devergne.   

Abstract

IL-27 induces stronger proliferation of naive than memory human B cells and CD4(+) T cells. In B cells, this differential response is associated with similar levels of IL-27 receptor chains, IL-27Rα and gp130, in both subsets and stronger STAT1 and STAT3 activation by IL-27 in naive B cells. Here, we show that the stronger proliferative response of CD3-stimulated naive CD4(+) T cells to IL-27 is associated with lower levels of IL-27Rα but higher levels of gp130 compared with memory CD4(+) T cells. IL-27 signaling differs between naive and memory CD4(+) T cells, as shown by more sustained STAT1, -3, and -5 activation and weaker activation of SHP-2 in naive CD4(+) T cells. In the latter, IL-27 increases G0/G1 to S phase transition, cell division and, in some cases, cell survival. IL-27 proliferative effect on naive CD4(+) T cells is independent of MAPK, but is dependent on c-Myc and Pim-1 induction by IL-27 and is associated with induction of cyclin D2, cyclin D3, and CDK4 by IL-27 in a c-Myc and Pim-1-dependent manner. In BCR-stimulated naive B cells, IL-27 only increases entry in the S phase and induces the expression of Pim-1 and of cyclins A, D2, and D3. In these cells, inhibition of Pim-1 inhibits IL-27 effect on proliferation and cyclin induction. Altogether, these data indicate that IL-27 mediates proliferation of naive CD4(+) T cells and B cells through induction of both common and distinct sets of cell cycle regulators.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21669870      PMCID: PMC3149329          DOI: 10.1074/jbc.M111.221010

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways.

Authors:  Toshiyuki Owaki; Masayuki Asakawa; Fumio Fukai; Junichiro Mizuguchi; Takayuki Yoshimoto
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Antiangiogenic and antitumor activities of IL-27.

Authors:  Motomu Shimizu; Mariko Shimamura; Toshiyuki Owaki; Masayuki Asakawa; Koji Fujita; Motoshige Kudo; Yoichiro Iwakura; Yasutaka Takeda; Andrew D Luster; Junichiro Mizuguchi; Takayuki Yoshimoto
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

3.  PIM1 and MYC: a changing relationship?

Authors:  Jean-Francois Naud; Martin Eilers
Journal:  Nat Cell Biol       Date:  2007-08       Impact factor: 28.824

4.  Augmentation of antigen-presenting and Th1-promoting functions of dendritic cells by WSX-1(IL-27R) deficiency.

Authors:  Sen Wang; Yoshiyuki Miyazaki; Yukari Shinozaki; Hiroki Yoshida
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

5.  IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38.

Authors:  George D Kalliolias; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

6.  Expression of interleukin-27 by human trophoblast cells.

Authors:  A Coulomb-L'Herminé; F Larousserie; S Pflanz; E Bardel; R A Kastelein; O Devergne
Journal:  Placenta       Date:  2007-07-30       Impact factor: 3.481

Review 7.  Advances in understanding the anti-inflammatory properties of IL-27.

Authors:  J S Stumhofer; C A Hunter
Journal:  Immunol Lett       Date:  2008-03-03       Impact factor: 3.685

8.  Interleukin-27 directly induces differentiation in hematopoietic stem cells.

Authors:  Jun Seita; Masayuki Asakawa; Jun Ooehara; Shin-Ichiro Takayanagi; Yohei Morita; Nobukazu Watanabe; Koji Fujita; Motoshige Kudo; Junichiro Mizuguchi; Hideo Ema; Hiromitsu Nakauchi; Takayuki Yoshimoto
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

9.  Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 27.

Authors:  Christine Brender; Gillian M Tannahill; Brendan J Jenkins; Joel Fletcher; Ruth Columbus; Christiaan J M Saris; Matthias Ernst; Nicos A Nicola; Douglas J Hilton; Warren S Alexander; Robyn Starr
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113

10.  Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27.

Authors:  Stefan Wirtz; Ingrid Tubbe; Peter R Galle; Hans J Schild; Mark Birkenbach; Richard S Blumberg; Markus F Neurath
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

View more
  16 in total

1.  The composition and signaling of the IL-35 receptor are unconventional.

Authors:  Lauren W Collison; Greg M Delgoffe; Clifford S Guy; Kate M Vignali; Vandana Chaturvedi; DeLisa Fairweather; Abhay R Satoskar; K Christopher Garcia; Christopher A Hunter; Charles G Drake; Peter J Murray; Dario A A Vignali
Journal:  Nat Immunol       Date:  2012-02-05       Impact factor: 25.606

2.  Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses.

Authors:  Stephan Wilmes; Polly-Anne Jeffrey; Jonathan Martinez-Fabregas; Maximillian Hafer; Paul K Fyfe; Elizabeth Pohler; Silvia Gaggero; Martín López-García; Grant Lythe; Charles Taylor; Thomas Guerrier; David Launay; Suman Mitra; Jacob Piehler; Carmen Molina-París; Ignacio Moraga
Journal:  Elife       Date:  2021-04-19       Impact factor: 8.140

3.  Distinctive cytokine, chemokine, and antibody responses in Echinococcus multilocularis-infected patients with cured, stable, or progressive disease.

Authors:  Xiangsheng Huang; Beate Grüner; Christian J Lechner; Peter Kern; Peter T Soboslay
Journal:  Med Microbiol Immunol       Date:  2014-02-09       Impact factor: 3.402

4.  Down-regulation of microRNA-451a facilitates the activation and proliferation of CD4+ T cells by targeting Myc in patients with dilated cardiomyopathy.

Authors:  Zhipeng Zeng; Ke Wang; Yuanyuan Li; Ni Xia; Shaofang Nie; Bingjie Lv; Min Zhang; Xin Tu; Qianqian Li; Tingting Tang; Xiang Cheng
Journal:  J Biol Chem       Date:  2016-12-14       Impact factor: 5.157

Review 5.  The role of Pim kinase in immunomodulation.

Authors:  Zhaoyun Liu; Mei Han; Kai Ding; Rong Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 6.  Interleukin-27: balancing protective and pathological immunity.

Authors:  Christopher A Hunter; Rob Kastelein
Journal:  Immunity       Date:  2012-12-14       Impact factor: 31.745

7.  IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin.

Authors:  Denada Dibra; Abhisek Mitra; Melissa Newman; Xueqing Xia; Camille Keenan; Jeffry J Cutrera; J Michael Mathis; Xiao-Jing Wang; Jeffrey Myers; Shulin Li
Journal:  Oncotarget       Date:  2016-11-22

8.  IL-27 Limits Type 2 Immunopathology Following Parainfluenza Virus Infection.

Authors:  Gaia Muallem; Sagie Wagage; Yan Sun; Jonathan H DeLong; Alex Valenzuela; David A Christian; Gretchen Harms Pritchard; Qun Fang; Elizabeth L Buza; Deepika Jain; M Merle Elloso; Carolina B López; Christopher A Hunter
Journal:  PLoS Pathog       Date:  2017-01-27       Impact factor: 6.823

9.  Interleukin-27R Signaling Mediates Early Viral Containment and Impacts Innate and Adaptive Immunity after Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors:  James A Harker; Kurt A Wong; Simone Dallari; Phuc Bao; Aleksandr Dolgoter; Yeara Jo; Ellen J Wehrens; Monica Macal; Elina I Zuniga
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

Review 10.  Interleukin-27 and Its Diverse Effects on Bacterial Infections.

Authors:  Yugo Morita; Elysia A Masters; Edward M Schwarz; Gowrishankar Muthukrishnan
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.